| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 |
| filingDate |
2013-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2018-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-104582721-B |
| titleOfInvention |
For preventing oral killed mycobacteria lungy |
| abstract |
The present invention relates to the killed mycobacterium for preventing oral use lungy, and it uses multiple dose scheme to be administered, and interval time reduction between dosage, so as to induce the tolerance foundation for being directed to mycobacterium tuberculosis infection.The bacterium of the inactivation can using aforementioned schemes come infection control from latence to active tuberculosis disease progression. |
| priorityDate |
2012-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |